| Literature DB >> 35330672 |
Kenji Tsuchihashi1,2, Yuki Hirata3, Juntaro Yamasaki2, Kentaro Suina2, Kenro Tanoue1, Toshifumi Yae2,4, Kenta Masuda5, Eishi Baba6, Koichi Akashi1, Yuko Kitagawa3, Hideyuki Saya2, Osamu Nagano2.
Abstract
Epithelial-mesenchymal plasticity (EMP) refers to the reversible cellular transition between epithelial and mesenchymal status. Spontaneous EMP is also reported in breast and prostate cancer, leading to the acquisition of stem-cell properties and chemoresistance. However, the presence of spontaneous EMP is still not reported in esophageal cancer. We screened 11 esophageal squamous cancer cell (ESCC) cell lines by CD44 isoform expression. KYSE520 was found to comprise heterogenous populations consisting of CD44v+ and CD44v- subpopulations. CD44v+ and CD44v- cells showed the expression of epithelial and mesenchymal markers, respectively. Single-cell sorting of CD44v+ and CD44v- cells revealed both cells gave rise to cell populations consisting of CD44v+ and CD44v- cells, indicating CD44v+ epithelial-like and CD44v- mesenchymal-like cells can generate counterparts, respectively. The ablation of Epithelial splicing regulatory protein 1 (ESRP1), a major regulator of CD44 mRNA splicing, resulted in the shift from CD44v+ to CD44v- cells in KYSE520. However, the expression of epithelial-mesenchymal transition (EMT)-related markers or transcriptional factors were almost not affected, suggesting ESRP1 functions downstream of EMP. Our results revealed the presence of spontaneous EMP in esophageal cancer and KYSE520 is useful model to understand spontaneous EMP.Entities:
Keywords: Alternative splicing; CD44; ESRP1; Epithelial-mesenchymal plasticity; Esophageal squamous cell carcinoma
Year: 2022 PMID: 35330672 PMCID: PMC8938278 DOI: 10.1016/j.bbrep.2022.101246
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1KYSE520 and TE8 cell lines are heterogeneous and comprise CD44v+ epithelial-like and CD44v– mesenchymal-like subpopulations. (A) Flow cytometric analysis of CD44v and pan-CD44 expression in 11 human ESCC cell lines. (B) Experimental protocol for sorting of KYSE520 and TE8 cells into CD44v+ and CD44v– subpopulations by FACS using the monoclonal antibody to CD44v9. (C) Semiquantitative RT-PCR analysis of CD44v and CD44s isoform mRNAs in CD44v+ and CD44v– subpopulations of KYSE520 and TE8 cells. GAPDH mRNA was examined as an internal control. The leftmost lane contains molecular size markers. (D) Quantitative RT-PCR analysis of mRNA abundance for EMT markers and TFs in CD44v+ versus CD44v– subpopulations of KYSE520 and TE8 cells. Data are means ± SD from four independent experiments. (E) Flow cytometric analysis of the expression of CD44v and the epithelial cell marker EpCAM in KYSE520 and TE8 cells.
Fig. 2Individual KYSE520 cells, but not TE8 cells, possess the ability to reconstitute a heterogeneous cell population consisting of CD44v+ and CD44v– cells. (A) Experimental protocol for single-cell sorting using the monoclonal antibody to CD44v9. and expansion of CD44v+ (#1+, #2+) and CD44v– (#1-, #2-) clones from KYSE520 and TE8 cell lines. (B) Flow cytometric analysis of EpCAM and CD44v expression in cell populations derived from single CD44v+ (#1+, #2+) or CD44v– (#1-, #2-) KYSE520 and TE8 cells. (C) Experimental protocol for the sorting of CD44v+ and CD44v– subpopulations derived from the #1- clone of KYSE520 cells using the monoclonal antibody to CD44v9 is shown on the left. Semiquantitative RT-PCR analysis of CD44 isoform mRNAs in these subpopulations is shown on the right. (D) Quantitative RT-PCR analysis of EMT-related markers and TFs in the CD44v+ subpopulation relative to the CD44v– subpopulation isolated as in (C). Data are means ± SD from four independent experiments. (E) Experimental protocol for a second single-cell sorting and expansion of CD44v+ (#1-1+, #1–2+) or CD44v– (#1-1-, #1-2-) clones derived from KYSE520 #1- cells. (F) Flow cytometric analysis of EpCAM and CD44v in the secondary CD44v+ (#1-1+, #1–2+) or CD44v– (#1-1-, #1-2-) clones in (E).
Fig. 3ESRP1 regulates CD44 pre-mRNA splicing without affecting EMT status. (A) Quantitative RT-PCR analysis of ESRP1 mRNA abundance in CD44v+ and CD44v– subpopulations of KYSE520 cells. Data are expressed relative to the corresponding normalized value for CD44v– cells and are means ± SD from four independent experiments. ***P < 0.001 (Student's t-test). (B) Semiquantitative RT-PCR analysis for CD44 isoform mRNAs in CD44v+ KYSE520 cells transfected with control or ESRP1 siRNAs. (C) Immunoblot analysis of CD44 and ESRP1 in KYSE520 clone #1- cells stably transfected with vectors for Control or ESRP1 (#1, # 2, #3) shRNAs. ESRP1 shRNA#2 failed to suppress ESRP1 expression. β-actin was examined as a loading control. (D) Flow cytometric analysis of CD44v and EpCAM expression in KYSE520 clone #1- cells stably expressing ESRP1 (#1, #3) or control shRNAs. (E) Quantitative RT-PCR analysis of EMT-related marker and TF mRNA abundance in KYSE520 clone #1- cells stably expressing ESRP1 (#1, #3) or control shRNAs. Data are expressed relative to the corresponding normalized value for cells expressing the control shRNA and are means + SD from four independent experiments. NS (not significant), *P < 0.05, **P < 0.01 (Student's t-test). (F) Flow cytometric analysis of CD44v and EpCAM expression in KYSE520 clones (#1-1- and #1-2-) stably expressing ESRP1 (#1, #3) or control shRNAs. (G) Flow cytometric analysis of KYSE520 clone (#1-1-) stably expressing ESRP1 (#1, #3) or control shRNAs knocked down by control or Zeb1 siRNA. (H) Quantitative RT-PCR analysis of EMT-related marker and TF mRNA abundance in KYSE520 cells incubated with or without TGF-β (10 ng/ml) and EGF (25 ng/ml) for 72 h. Data are expressed relative to the corresponding normalized value for nontreated cells and are means + SD from four independent experiments. NS, *P < 0.05, **P < 0.01, ***P < 0.001 (Student's t-test). (I) Quantitative RT-PCR analysis of ESRP1 expression in KYSE520 cells treated as in (H). (J) Flow cytometric analysis of CD44v and EpCAM expression in KYSE520 cells treated as in (G).